for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax signs deal with SK Bioscience for 40 mln vaccine doses for S. Korea

Feb 15 (Reuters) - U.S. drug developer Novavax Inc said on Monday it has signed a license agreement with South Korea manufacturer SK Bioscience to produce 40 million doses of its COVID-19 vaccine for South Korea.

"Concurrently, SK Bioscience has finalized an advance purchase agreement with the Korean government to supply 40 million doses of NVX-CoV2373 to the Republic of Korea beginning in 2021", Novavax said in a statement bit.ly/37eMKB2.

Reporting by Kanishka Singh in Bengaluru; Editing by Kim Coghill

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up